Peptides for libido and sexual health — what research has explored beyond Viagra

Medicine has historically been better at addressing the mechanical components of sexual dysfunction than the experiential ones. PDE5 inhibitors — sildenafil (Viagra), tadalafil (Cialis) — are among the most commercially successful drugs in history, and they work well for what they do: they increase genital blood flow by inhibiting the enzyme that degrades cyclic GMP, facilitating erection in men with vascular erectile dysfunction. But they do not address desire. A man who takes sildenafil and has no interest in sex will experience a vascular response; he will not experience the rekindling of wanting. And women with low sexual desire — hypoactive sexual desire disorder, or HSDD — had, for decades, essentially no FDA-approved pharmacological option. The gap between what medicine could offer and what people were actually experiencing as sexual health problems was wide. Peptide research, in this context, has come from a genuinely different direction: not vascular, but central. Not the plumbing, but the brain.

PT-141, now known as bremelanotide and marketed as Vyleesi, is the peptide with the strongest evidence base and the most direct regulatory history in this category. It is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates melanocortin receptors — specifically MC3R and MC4R — in the central nervous system. This is the mechanism that distinguishes it fundamentally from sildenafil: PT-141 acts in the brain, not the periphery. The melanocortin system in the CNS is involved in appetite regulation, sexual behavior, and social reward, and its role in sexual arousal was not initially obvious — it emerged partly from incidental observations in clinical trials.

The origin story of bremelanotide involves Melanotan II, a synthetic analogue of alpha-MSH developed in the 1980s at the University of Arizona, originally as a potential tanning agent. When researchers and eventually self-experimenting individuals observed that MT-II reliably induced erections and spontaneous arousal as side effects, the sexual applications became the primary research interest. PT-141 was developed as a derivative that separated the melanocortin-mediated arousal and sexual function effects from the full tanning and other properties of MT-II. Bremelanotide (Vyleesi) was FDA-approved in June 2019 as the first FDA-approved pharmacological treatment for HSDD in premenopausal women — a meaningful milestone given how long this indication had been unmet. It is administered as a subcutaneous injection taken 45 minutes before anticipated sexual activity, and clinical trials showed statistically significant improvements in sexual desire and satisfying sexual events compared to placebo. The effect size is moderate rather than dramatic; the most common side effect is nausea, which is why it is dosed and not taken daily. It is also used off-label in men, where clinical observations and early research suggest effects on arousal and erectile function through central mechanisms — though the FDA approval is specifically for premenopausal women with HSDD.

Melanotan II itself, the parent compound, is worth knowing about in this context but is not a clinical recommendation. It is not FDA-approved, is sold as a research compound, and its broader receptor activity — including effects on pigmentation, appetite suppression, and cardiovascular tone — makes unsupervised use particularly risky. The development of PT-141/bremelanotide specifically was an attempt to retain the sexual function signal while narrowing the receptor activity profile.

The hypothalamic-pituitary-gonadal (HPG) axis is the hormonal command system for sexual function, and several peptides operate in this system at different points. Kisspeptin-10 is a fragment of kisspeptin — a neuropeptide produced in the hypothalamus that is one of the primary upstream activators of the entire HPG axis. Kisspeptin neurons fire, GnRH (gonadotropin-releasing hormone) is released, which triggers LH and FSH from the pituitary, which then drive testosterone and estradiol production from the gonads. This is the foundational signaling cascade that produces the sex hormones on which libido, arousal, and reproductive function depend. Kisspeptin-10 has been studied in human clinical research — it has been shown to reliably stimulate LH release, to amplify the neurological response to erotic stimuli in men (in a study from the Wellcome Trust Centre for Neuroimaging), and to influence sexual behavior and arousal through central mechanisms. It is investigational — not FDA-approved, not in standard clinical use — but it has a developing human trial record and a mechanistically compelling position in this landscape as a potentially upstream hormonal amplifier.

Gonadorelin is a synthetic GnRH analogue. GnRH is the hypothalamic hormone that pulses every 60-90 minutes under normal physiological conditions to stimulate LH and FSH from the pituitary. Gonadorelin is used clinically in diagnostic testing of pituitary function, and in fertility medicine. Its relevance to sexual health in the optimization context is primarily in the setting of testosterone replacement therapy: exogenous testosterone suppresses the HPG axis, reducing LH stimulation to the testes and leading to testicular atrophy and infertility. Gonadorelin, given in pulsatile subcutaneous injection to mimic natural hypothalamic signaling, is used to maintain testicular function and LH stimulation in men on TRT. It is FDA-approved for specific diagnostic and fertility indications. It is not a libido treatment per se, but it is meaningfully relevant to sexual health in the TRT context.

Human chorionic gonadotropin (hCG) acts at the same point in this system — it mimics LH and directly stimulates testicular testosterone production and testicular volume maintenance. hCG has been widely used alongside TRT for the same reasons as gonadorelin, and it has a longer clinical history in that application. It is FDA-approved in fertility contexts. In the sexual health conversation, hCG matters because preserving testicular function on TRT has implications for intratesticular testosterone (which is critical for sperm production and may contribute to libido in ways that systemic testosterone does not fully replicate), as well as for the felt experience of normal gonadal function.

Oxytocin is one of the most over-simplified compounds in popular health discourse, and the sexual health context is where that oversimplification is particularly pronounced. Oxytocin is produced in the hypothalamus and released by the posterior pituitary during childbirth, breastfeeding, orgasm, and physical touch. It plays roles in pair bonding, trust, social recognition, and uterine contraction. The "love hormone" framing that has dominated its popular narrative captures something real — it is involved in the neurochemistry of attachment and bonding — but it dramatically overstates both the scope and the directionality of its effects. Oxytocin's actual pharmacological effects in humans are highly context-dependent, are modulated by existing social relationships and personality characteristics, and do not cleanly translate into predictable improvements in desire or intimacy. Some research has shown that intranasal oxytocin can increase self-reported feelings of trust and reduce social anxiety, and some early human studies have explored its effects on sexual satisfaction and bonding in couples. The evidence for intranasal oxytocin as a sexual health intervention — in the sense of reliably improving libido, function, or relationship intimacy — is not developed. It is mentioned here because it appears frequently in this conversation and deserves an honest placement: the biology is interesting and the research is ongoing, but the "oxytocin for intimacy" narrative has run well ahead of what the evidence supports.

The relationship between hormonal optimization and sexual health is the most clinically important piece of this landscape, and it precedes any discussion of peptides. Testosterone is the primary driver of libido in both men and women. Low testosterone in men — whether from primary hypogonadism, secondary hypogonadism from pituitary dysfunction, or age-related decline — produces reliably reduced libido, often alongside fatigue, mood changes, and reduced erectile function. In women, testosterone at much lower levels plays a similarly important role in desire; the sharp drop in testosterone that accompanies menopause or surgical oophorectomy is one of the most predictable causes of HSDD. Estradiol status in women affects vaginal health, lubrication, and physical comfort during sex in ways that profoundly affect both function and desire. Optimizing sex hormone levels is, for many people, the intervention that matters most for sexual health — and it is foundational before peptide conversations make clinical sense.

Mental health, relationship dynamics, sleep, and chronic stress are the other foundational layers that pharmaceutical and peptide interventions cannot bypass. Chronic stress suppresses the HPG axis through cortisol-mediated inhibition — this is a well-characterized physiological mechanism, not a metaphor. Poor sleep reduces testosterone. Relationship conflict, trust deficits, and unaddressed psychological factors around sex are not responsive to melanocortin agonism. PDE5 inhibitors and PT-141 both have real evidence, but neither creates desire from nothing in someone whose libido problem is fundamentally relational, psychological, or driven by uncorrected hormonal deficiency.

Addyi (flibanserin), the other FDA-approved drug for HSDD, is worth naming in this context even though it is not a peptide. It is a serotonin receptor agonist/antagonist that modulates dopamine and serotonin balance in neural circuits involved in sexual motivation. Its approval was contested and its effect size is modest, but it represents the same therapeutic insight as bremelanotide: that female sexual desire is a central nervous system phenomenon that deserves pharmacological consideration, not a problem to be managed by telling women to "relax."

The peptide sexual health landscape, honestly summarized, has one compound with solid FDA-approved evidence in women (bremelanotide), one compound (kisspeptin) with a growing and mechanistically compelling human research record at the investigational stage, and several compounds (gonadorelin, hCG) with established clinical applications adjacent to sexual health in hormone optimization contexts. The broader claims about oxytocin and libido, about Melanotan II, and about various other melanocortin-adjacent compounds outpace the evidence. The foundational work — hormonal evaluation, sleep, stress, relationship health — matters more than any compound. What peptide research is offering in this space is not a replacement for that evaluation but, in specific circumstances and with appropriate clinical oversight, a tool that addresses mechanisms conventional medicine has historically neglected. That is a genuine contribution. Evaluating it honestly, with a prescribing provider who understands both the evidence and the individual's full clinical and relational context, is where that contribution can be most carefully applied.